Triple therapy targets tough brain metastases in lung cancer

NCT ID NCT06431685

Recruiting now Disease control Sponsor: Sichuan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study is testing whether a combination of low-dose radiation to the whole brain, an immunotherapy drug (PD-1 inhibitor), and chemotherapy given directly into the spinal fluid can safely treat lung cancer that has spread to the lining of the brain and spinal cord. The trial will enroll 10 adults aged 18-75 whose cancer has not responded to standard treatments. Researchers will monitor side effects and check if the cancer shrinks or stops growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Whole brain low-dose radiotherapy, pembrolizumab (PD-1 inhibitor), and pemetrexed (intrathecal chemotherapy)
What this could lead to: If successful, this combination could offer a new treatment option for people with lung cancer that has spread to the brain and spinal cord lining, potentially improving survival and quality of life.
What could go wrong: This is a very early (Phase 1) and small study with only 10 participants, so results may not apply to everyone. The combination of treatments may cause serious side effects, including brain inflammation or nerve damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEPTOMENINGEAL METASTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Meningeal Carcinomatosis neoplastic meningitis non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEPTOMENINGEAL METASTASIS LOW-DOSE RADIOTHERAPY NSCLC PD-1 INHIBITOR

Contacts and locations

Locations

West China Hospital, Sichuan University
RECRUITING

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.